The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy
Open accessAbstract
Glycogen synthase kinase 3 (GSK3) is a multifunctional serine/threonine kinase that participates in numerous signalling pathways involved in diverse physiological processes. Several of these pathways are implicated in disease pathogenesis, which has prompted efforts to develop GSK3-specific inhibitors for therapeutic applications. However, before now, there has been no strong rationale for targeting GSK3 in malignancies. Here we report pharmacological, physiological and genetic studies that demonstrate an oncogenic requirement for GSK3 in the maintenance of a specific subtype of poor prognosis human leukaemia, genetically defined by mutations of the MLL proto-oncogene. In contrast to its previously characterized roles in suppression of neoplasia-associated signalling pathways, GSK3 paradoxically supports MLL leukaemia cell proliferation and transformation by a mechanism that ultimately involves destabilization of the cyclin-dependent kinase inhibitor p27(Kip1). Inhibition of GSK3 in a preclinical murine model of MLL leukaemia provides promising evidence of efficacy and earmarks GSK3 as a candidate cancer drug target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plethora of studies in last decade showed that active GSK3b is involved in the regulation of number of pathways that can influence leukemogenesis, leukemia cell survival (13,46), myeloid differentiation, and resistance to chemotherapy.”
From FBW7 Inhibits Myeloid Differentiation in Acute Myeloid Leukemia via GSK3-Dependent Ubiquitination of PU.1 (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“in some of the AMLs, GSK3b was shown to act as tumor promoter by targeting tumor suppressors such as p27 (13).”
From FBW7 Inhibits Myeloid Differentiation in Acute Myeloid Leukemia via GSK3-Dependent Ubiquitination of PU.1 (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Sato, N., Meijer, L., Skaltsounis, A., Greengard, P., & Brivanlou, A. H. (2003) · Nature Medicine · doi:10.1038/nm979 · Cited by 2,139
GSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084
Cohen, P., & Frame, S. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096075 · Cited by 1,493
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stabilityPreprint
Sears, R. C., Nuckolls, F., Haura, E. B., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,411
Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation
Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M., Jin, O., & Woodgett, J. R. (2000) · Nature · doi:10.1038/35017574 · Cited by 1,401
Yost, C., Torres, M., Miller, J., Huang, E., Kimelman, D., & Moon, R. T. (1996) · Genes & Development · doi:10.1101/gad.10.12.1443 · Cited by 1,167
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
Yilmaz, Ö. H., Valdez, R., Theisen, B. K., Guo, W., Ferguson, D. O., Wu, H., & Morrison, S. J. (2006) · Nature · doi:10.1038/nature04703 · Cited by 1,113
Martin, M., Rehani, K., Jope, R. S., & Michalek, S. M. (2005) · Nature Immunology · doi:10.1038/ni1221 · Cited by 1,099
Yokoyama, A., Somervaille, T. C. P., Smith, K. S., Rozenblatt–Rosen, O., Meyerson, M. M., & Cleary, M. L. (2005) · Cell · doi:10.1016/j.cell.2005.09.025 · Cited by 698
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Miller, J. R. The Wnts. Genome Biol 3, 3001 (2002)
Cited by
Sorted by citations
Items 201–269 of 269
SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG
Wang, S., Wang, X., Du, Z., Liu, Y., Huang, D., Zheng, K., Liu, K., Zhang, Y., Zhong, X., & Wang, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.05.076 · Cited by 11
Wnt Signaling in Leukemias and Myeloma: T-Cell Factors are in Control
Tiemessen, M. M., & Staal, F. J. T. (2013) · Future Oncology · doi:10.2217/fon.13.122 · Cited by 11
Aberrant expression of glycogen synthase kinase‑3β in human breast and head and neck cancer
Ugolkov, A. V., Matsangou, M., Taxter, T., O’Halloran, T. V., Cryns, V. L., Giles, F. J., & Mazar, A. P. (2018) · Oncology Letters · doi:10.3892/ol.2018.9483 · Cited by 11
To, C., Roy, A., Chan, E. W. C., Prado, M. A. M., & Guglielmo, G. M. D. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.03.012 · Cited by 11
de Candia, P., Minopoli, G., Verga, V., Gargiulo, A., Vanoni, M., & Alberghina, L. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.047 · Cited by 10
Bone marrow localization and functional properties of human hematopoietic stem cells
Boyd, A. L., & Bhatia, M. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000055 · Cited by 10
Interaction of manzamine A with glycogen synthase kinase 3β: a molecular dynamics study
Osolodkin, D. I., Shulga, D. A., Palyulin, V. A., & Zefirov, N. S. (2010) · Russian Chemical Bulletin · doi:10.1007/s11172-010-0344-4 · Cited by 10
Higgins, M. J., Beaver, J. A., Wong, H. Y., Gustin, J. P., Lauring, J. D., Garay, J. P., Konishi, H., Mohseni, M., Wang, G. M., Cidado, J. R., et al. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.3.14227 · Cited by 9
Meredith, G. D., D’Ippolito, A. M., Dudas, M., Zeidner, L. C., Hostetter, L. J., Faulds, K. J., Arnold, T. H., Popkie, A. P., Doble, B. W., Marnellos, G., et al. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-01-0013 · Cited by 9
The emerging role of GSK‐3β in the pathobiology of classical Hodgkin lymphoma
Agostinelli, C., Carloni, S., Limarzi, F., Righi, S., Laginestra, M. A., Musuraca, G., Fiorentino, M., Napolitano, R., Cuneo, A., Vergara, D., et al. (2017) · Histopathology · doi:10.1111/his.13189 · Cited by 9
Novel methods and approaches to acute lymphoblastic leukemia drug discovery
Wei, M. C., & Cleary, M. L. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.956720 · Cited by 9
Self-citationSmall Molecular Immune Modulators as Anticancer Agents
Han, Y., Zhu, L., Wu, W., Zhang, H., Hu, W., Dai, L., & Yang, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_22 · Cited by 8
IKK-β/NF-κB p65 mediates p27Kip1 protein degradation in arsenite response
Guo, W., Liu, J., Jian, J., Li, J., Wan, Y., & Huang, C. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.04.055 · Cited by 8
Re-Expression of ERα and AR in Receptor Negative Endocrine Cancers via GSK3 Inhibition
Sharma, V., Joshi, J., Yeh, I., Doughman, Y., Blankenberg, D. J., Wald, D. N., & Montano, M. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.824594 · Cited by 9
Crozier, R. W. E., Fajardo, V. A., & MacNeil, A. J. (2022) · European Journal of Immunology · doi:10.1002/eji.202250104 · Cited by 7
Kim, N., Kim, M. Y., Choi, W. S., Yi, E., Lee, H. J., & Kim, H. S. (2021) · Cancers · doi:10.3390/cancers13081802 · Cited by 7
Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario
Cândido, M. F., Medeiros, M., Veronez, L. C., Bastos, D., Oliveira, K. L., Pezuk, J. A., Valera, E. T., & Brassesco, M. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020664 · Cited by 8
Pardhi, T. R., Patel, M. S., Sudarsanam, V., & Vasu, K. K. (2018) · MedChemComm · doi:10.1039/c8md00321a · Cited by 7
Yoshino, Y., Suzuki, M., Takahashi, H., & Ishioka, C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.06.142 · Cited by 7
Wnt-induced proteolytic targeting: Figure 1.Preprint
Jones, K. A., & Kemp, C. R. (2008) · Genes & Development · doi:10.1101/gad.1741008 · Cited by 7
Multiplex Screening for Interacting Compounds in Paediatric Acute Myeloid Leukaemia
Cairns, L. V., Lappin, K. M., Mutch, A., Ali, A., Matchett, K. B., & Mills, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810163 · Cited by 6
Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects
Peixoto-da-Silva, J., Calgarotto, A. K., Rocha, K. R., Palmeira-dos-Santos, C., Smaili, S. S., Pereira, G. J. S., Pericole, F. V., Duarte, A. S. S., Saad, S. T. O., & Bincoletto, C. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.027 · Cited by 6
Ding, L., Roeck, K., Zhang, C., Zidek, B., Rodman, E., Hernandez-Barco, Y. G., Zhang, J.-S., Bamlet, W., Oberg, A., Zhang, L.-Z., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.853003 · Cited by 6
Yokoyama, N., Nakayama, H., & Iwabuchi, K. (2023) · Cells · doi:10.3390/cells12020322 · Cited by 5
GSK‑3β mediates the effects of HNF‑1β overexpression in ovarian clear cell carcinoma
Kawahara, N., Mizutani, A., Matsubara, S., Takeda, Y., & Kobayashi, H. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9250 · Cited by 5
The role of glycogen synthase kinase-3β in glioma cell apoptosis induced by remifentanil
Xu, J., Xu, P., Li, Z., Lu, X., & Yang, Z. R. (2013) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-013-0102-3 · Cited by 5
Mathuram, T. L. (2024) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2024.0025 · Cited by 4
E3 ubiquitin ligases in the acute leukemic signaling pathways
Zhan, Q., Zhang, H., Wu, B., Zhang, N., & Zhang, L. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1004330 · Cited by 4
Serine-Threonine Protein Kinases CK1, CK2 and GSK3 in Normal and Malignant Haematopoiesis
Piazza, F., Manni, S., Colpo, A., Tubi, L. Q., Gurrieri, C., & Semenzato, G. (2011) · Current Signal Transduction Therapy · doi:10.2174/157436211794109370 · Cited by 4
Targeting Wnt Signaling in Acute Lymphoblastic Leukemia
Hurwitz, S., Lee, K. J., Fourfouris, T., Choi, I. F., Parikh, K., Friedmann, R., Zarrabi, M., & Kim, Y. (2025) · Cancers · doi:10.3390/cancers17152456 · Cited by 3
Arroyo-Berdugo, Y., Mambro, A. D., Behrends, V., Sahai, M. A., Cozzuto, L., Zollo, I., Ponomarenko, J. V., Williams, O., Gribben, J. G., Calle, Y., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70158 · Cited by 3
Oncogenic Fusions with Aberrant Transcriptional Regulation
You, K., Chen, T., Wang, Y., Li, P., & Li, T. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169268 · Cited by 3
A Novel AKR1C3 Specific Prodrug TH3424 With Potent Antitumor Activity in Liver Cancer
He, P., Wang, C., Wang, Y., Wang, C., Zhou, C., Cao, D., Li, J., Bushnell, D. A., Li, Q., Kornberg, R. D., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2171 · Cited by 3
Self-citationRetractedExploring an anomaly: the synthesis of 7,7′-diazaindirubin through a 7-azaindoxyl intermediate
Shriver, J. A., Wang, K. R., Patterson, A. C., DeYoung, J. R., & Lipsius, R. J. (2020) · RSC Advances · doi:10.1039/d0ra07144g · Cited by 5
Signaling pathways and regulation of gene expression in hematopoietic cells
Bogush, D., Schramm, J. W., Ding, Y., He, B., Singh, C. R., Sharma, A. K., Tukaramrao, D. B., Iyer, S., Desai, D. H., Nalesnik, G. H., et al. (2022) · Advances in Biological Regulation · doi:10.1016/j.jbior.2022.100942 · Cited by 3
Lee, Y., Wang, L., Huang, C., Chiou, J., Shi, Y., & Chang, L. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114047 · Cited by 3
Telomere Maintenance and Oncogenesis
Torres-Montaner, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210941 · Cited by 3
Distinct Pathologic Roles for Glycogen Synthase Kinase 3β in Colorectal Cancer Progression
Minamoto, T., Nakada, M. K. M., Shimasaki, T., Motoo, Y., & Kawakami, K. (2012) · InTech eBooks · doi:10.5772/28036 · Cited by 2
Dharmarajan, V., & Michael, S. (2011) · InTech eBooks · doi:10.5772/19754 · Cited by 2
Bipolar Disorder Treatments and Ovarian Cancer: A Systematic Review.
Miniati, M., Conversano, C., Palagini, L., Buccianelli, B., Fabrini, M. G., Mancino, M., Laliscia, C., Marazziti, D., Paiar, F., & Gemignani, A. (2020) · PubMed Central · doi:10.36131/cnfioritieditore20200508 · Cited by 2
Differentiation and Cell Survival of Myeloid Leukemia Cells
Studzinski, G. P., Brown, G., Danilenko, M., Hughes, P., & Marcinkowska, E. (2012) · Leukemia Research and Treatment · doi:10.1155/2012/370375 · Cited by 2
Cai, J., Zhang, N., Qiu, L., Dou, B.-T., Li, M., Chen, D., Ren, S.-H., Ma, L., Yao, H., & Fan, F. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42537 · Cited by 1
Molecularly Targeted Therapy for Infant ALL
Brown, P. A., & Felix, C. A. (2010) · Springer eBooks · doi:10.1007/978-0-387-69062-9_3 · Cited by 1
The regulation of constitutive NF-κB activity by glycogen synthase kinase-3 in pancreatic cancer
Wilson, W. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/z8xy-n262 · Cited by 1
Felix, C. A. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511977633.032 · Cited by 1
Obeidi, N., Babolei, M., Khamisipour, G., Mohammadi, S. A., Farhangdoost, F., & Valipor, S. (2023) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2023.24.8.2691 · Cited by 1
The Role of PIK3CA Mutations as A Predictor of Outcomes and A Therapeutic Target
Wang, G. M., & Park, B. H. (2010) · Current Breast Cancer Reports · doi:10.1007/s12609-010-0022-4 · Cited by 1
Pharmacological modulation of cell functional activity with valproic acid and erythropoietin
Александровна, Г. П., Sarycheva, M. V., Burda, S. Y., Puzanov, M. V., Nadezhdina, N. A., Kulikovskiy, V. F., Nadezhdin, S. V., Korokin, M. V., & Burda, Y. E. (2019) · Research Results in Pharmacology · doi:10.3897/rrpharmacology.5.34710 · Cited by 1
The role of cFLIP in breast cancer stem cells
French, R. (2014) · ORCA Online Research @Cardiff (Cardiff University)
Targeting Leukemia Stem Cells and Stem Cell Pathways in ALL
Pridans, C., & Huntly, B. J. P. (2011) · Springer eBooks · doi:10.1007/978-1-4419-8459-3_8
Reviewsynthase kinase 3 beta: can it be a target for oral cancer
Mishra, R. (2010)
Place des psychotropes en oncologie
Reich, M., & Bondenet, X. (2018) · Psycho-Oncologie · doi:10.3166/pson-2018-0035
Hernandez‐Davies, J. E., Zape, J. P., Landaw, E. M., Tan, X., Presnell, A., Griffith, D., Heinrich, M. C., Glaser, K. B., & Sakamoto, K. M. (2023) · doi:10.1158/1535-7163.c.6535200.v1
Lee, J. K., Chatterjee, A., Scarpa, M., Bailey, C. M., Niyongere, S., Singh, P., Ali, M. K. M., Kapoor, S., Wang, Y., Silvestri, G., et al. (2024) · doi:10.1158/2767-9764.c.7078148.v1
PP2A dependent and independent effects of forskolin in KMT2A (MLL)-rearranged acute leukaemiaPreprint
Arroyo-Berdugo, Y., Mambro, A. D., Behrends, V., Sahai, M. A., Cozzuto, L., Zollo, I., Ponomarenko, J. V., Williams, O., Gribben, J. G., Calle, Y., et al. (2024) · doi:10.22541/au.171913671.15017034/v1
A Review Progress on Homoharringtonine’s Effect on Acute Myeloid Leukemia
Fu, L., & Zhou, H. (2024) · Current Cancer Therapy Reviews · doi:10.2174/0115733947317749240918113844
Wnt in Hematopoietic and Leukemic Stem Cells
Dao, K.-H. T., & Catriona, H. M. J. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-347-3_8
Drug resistance in chronic myeloid leukemia: the involvement of Galectin-1 and Galectin-3
Yıldırım, C. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11473-y
Identification and Characterization of New Therapeutic Targets in Acute Myeloid Leukemia
Benajiba, L. (2018) · theses.fr (ABES) · doi:10.70675/76ba4ad8zc347z4443za6a1zc67553b19089
Double burden of cancer and bipolar disorder: Implications for mental health care
Marano, G., Sottile, A., Giacomi, O. D., Lanzetta, M., Scialpi, C., Pavese, F., Ricozzi, V., Rotondaro, S., Migliore, A., D’Angelo, T., et al. (2026) · World Journal of Psychiatry · doi:10.5498/wjp.120545
Li, Z., Pei, Y., Zhang, Z., Zheng, S., Li, Y., Wu, Q., Wang, J., yang, H., Li, R., Zheng, L., et al. (2026) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2026.08.030
BindingDB (2016) · UC San Diego · doi:10.7270/q2ft8ns4
Metadata
- Authors
- Wang, Z., Smith, K. S., Murphy, M., Piloto, O., Somervaille, T. C. P., & Cleary, M. L.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Cleary, Michael L.
- Venue
- Nature
- Published
- 2008-09-17
- Volume
- 455
- Issue
- 7217
- Pages
- 1205-1209
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4084721
- OpenAlex
- W1964632863
- Cited by
- 265
- References
- 43
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 6 · 2023: 8 · 2022: 9 · 2021: 10 · 2020: 17 · 2019: 14 · 2018: 13 · 2017: 13 · 2016: 14 · 2015: 14 · 2014: 23 · 2013: 29 · 2012: 26
- FWCI
- 19.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- David and Lucile Packard Foundation
- Lawrence Foundation
- National Cancer Institute (CA 116606, R01CA116606, CA-55029, R01CA055029)
- Topics
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glycogen synthase kinase-3, p27, cyclin-dependent kinase inhibitors, GSK-3 inhibitors, oncogenic signaling, therapeutic target
- MeSH terms
- Proto-Oncogene Mas, Animals, Cell Division, Cell Line, Transformed, Cell Transformation, Neoplastic, Disease Models, Animal, Humans, Isoenzymes, Leukemia, Lymphoid, Mice, Inbred C57BL, Histone-Lysine N-Methyltransferase, G1 Phase, Mice, SCID, Myeloid Progenitor Cells, Glycogen Synthase Kinase 3, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p27, Mice, Myeloid-Lymphoid Leukemia Protein, Precursor Cells, B-Lymphoid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
